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Abstract
Background: Growth/differentiation factor 8 (GDF8) and GDF11 are two highly similar members of the transforming
growth factor β (TGFβ) family. While GDF8 has been recognized as a negative regulator of muscle growth and
differentiation, there are conflicting studies on the function of GDF11 and whether GDF11 has beneficial effects on
age-related dysfunction. To address whether GDF8 and GDF11 are functionally identical, we compared their signaling
and structural properties.
Results: Here we show that, despite their high similarity, GDF11 is a more potent activator of SMAD2/3 and signals
more effectively through the type I activin-like receptor kinase receptors ALK4/5/7 than GDF8. Resolution of the GDF11:
FS288 complex, apo-GDF8, and apo-GDF11 crystal structures reveals unique properties of both ligands, specifically in
the type I receptor binding site. Lastly, substitution of GDF11 residues into GDF8 confers enhanced activity to GDF8.
Conclusions: These studies identify distinctive structural features of GDF11 that enhance its potency, relative to GDF8;
however, the biological consequences of these differences remain to be determined.
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Background
The transforming growth factor β (TGFβ) superfamily
of secreted proteins comprises more than 30 structur-
ally related, yet functionally distinct proteins that play
critical roles in embryological tissue development and
patterning, wound healing, and adult tissue mainten-
ance (reviewed in [1–5]). The TGFβ superfamily can be
divided into three subclasses: TGFβs, bone morpho-
genetic proteins (BMPs), and activins/inhibins. Growth/
differentiation factors 8 and 11 (GDF8/myostatin and
GDF11/BMP11, respectively) are two closely related
members of the activin/inhibin subclass that share ~90%
sequence identity in their mature, C-terminal signaling
domains and ~52% identity in their N-terminal prodo-
mains. GDF8 and GDF11 bind to similar receptors [6–8]
and extracellular antagonists [6, 9, 10], leading to the
assumption that mature GDF8 and GDF11 ligands are
functionally indistinguishable. While it is clear that GDF8
and GDF11 share many commonalities, including overlap-
ping or redundant roles in certain biological processes
[11–17], there is accumulating evidence that the two li-
gands may be functionally distinct [13, 18–23].
Gdf8 is expressed postnatally by skeletal and cardiac
muscle and therein negatively regulates skeletal muscle
mass by suppressing both the number and size of indi-
vidual muscle fibers [6, 18, 19, 24]. In contrast, GDF11
appears to act more broadly, regulating anterior/pos-
terior patterning and development of multiple organs/
tissues [11, 13]. Many tissues express Gdf11 postna-
tally, including the spleen, pancreas, kidney, and skeletal
muscle [11, 25–28]. However, determination of GDF11’s
exact role in the adult has remained elusive due to the
embryonic lethality of Gdf11-/- mice [11, 13]. In stark
contrast, Gdf8-/- mice survive into adulthood and have
a profound hypermuscular phenotype, which can be re-
capitulated in wild-type mice using natural occurring
antagonists of GDF8, such as follistatin (FS), follistatin-
* Correspondence: Tom.Thompson@uc.edu
1Department of Molecular Genetics, Biochemistry, and Microbiology,
University of Cincinnati, Cincinnati, OH 45267, USA
9University of Cincinnati, 231 Albert Sabin Way ML 0524, Cincinnati, OH
45267, USA
Full list of author information is available at the end of the article
© Thompson et al. 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Walker et al. BMC Biology  (2017) 15:19 
DOI 10.1186/s12915-017-0350-1
like 3 (FSTL3), and growth/differentiation factor-associated
serum protein 1 (GASP1) [6, 29–33]. Interestingly,
Gdf8-/-/Gdf11-/- mice have exaggerated homeotic axial
transformations compared to Gdf11-/- mice, suggesting
that GDF8 and GDF11 have redundant functions in
skeletal patterning [13]. However, muscle-specific
knockout of Gdf11 does not result in significant in-
creases in muscle mass and circulating GDF11 does not
overcome the hypermuscular phenotype found in
Gdf8-/- mice, suggesting that GDF8 and GDF11 do not
serve redundant roles in regulating skeletal muscle
mass [13]. Thus, while it is clear that loss of one ligand
compared to the other yields drastically different phe-
notypes, it has been argued that these differences relate
primarily to differential localization of ligand expres-
sion and do not reflect differences in ligand signaling.
Similar to other TGFβ ligands, GDF8 and GDF11 are
disulfide-linked dimers that are initially synthesized as
precursors, which are cleaved by furin-like proteases to
separate the N-terminal prodomain from the C-terminal
mature domain [6, 18, 34]. Unlike most TGFβ ligands,
mature GDF8 and GDF11 remain tightly bound to their
prodomains, holding them in a latent state [9, 34–37].
Ligand activation requires additional cleavage of the
prodomain by BMP1/tolloid (TLD) metalloproteinases
[9, 34–37]. The ligand dimer elicits signal transduction
by symmetrically binding two type II and two type I
transmembrane serine/threonine kinase receptors
(reviewed in [38]). Ligand-induced receptor clustering
leads to phosphorylation of SMAD2 and SMAD3
(SMAD2/3) transcription factors by the type I receptor.
Subsequent accumulation of SMAD2/3 in the nucleus
results in activation or repression of GDF8 and GDF11
responsive genes (Fig. 1a) [6–8]. Similar to other li-
gands in the activin/inhibin subclass, GDF8 and GDF11
predominantly signal through the type II receptors,
activin receptor kinase IIA (ActRIIA; ACVR2A) and
ActRIIB (ACVR2B) and the type I receptors, activin-
like receptor kinase 4 (ALK4; ACVR1B) and ALK5
(TβRI; Fig. 1a) [6–8]. There is also evidence that
GDF11 can signal using the type I receptor ALK7
(ACVR1C) [8]. Furthermore, signaling by both GDF8
and GDF11 is controlled by extracellular protein antag-
onists, including FS [6, 39], FSTL3 [9], GASP1, and
GASP2 [10, 40–42].
There have been conflicting reports comparing the
biological functions of GDF8 and GDF11, with some
question as to whether the two ligands are functionally
equivalent [16, 17, 20–23, 43, 44]. Specifically, GDF11
was identified as a circulating factor that declines with
age, and exogenous delivery of the mature ligand re-
versed many pathologies associated with aging [22, 23],
including reducing age-related cardiac hypertrophy [22],
improving skeletal muscle performance and repair [21],
improving olfaction [20], and increasing neurogenesis
[20]. Conversely, other reports have challenged these
claims, arguing that GDF8 and GDF11 are functionally
and biologically equivalent [16, 17, 43, 44]. However, it is
difficult to compare the results, given that many of these
studies did not utilize the same experimental design,
sources of recombinant proteins, or strategies for detec-
tion of GDF8 and GDF11 proteins (recently reviewed in
[5, 45]). Therefore, the extent of functional overlap
between mature GDF8 and GDF11 without the prodo-
main remains to be determined. Furthermore, a rigorous
side-by-side biochemical and biological comparison of
mature GDF8 and GDF11 has yet to be performed to
determine if distinct features exist between these growth
factors.
In this study, using a variety of in vitro and in vivo sys-
tems, we show that GDF11 is significantly more potent
than GDF8 and that the enhanced activity is due to dif-
ferences in type I receptor utilization. In addition, we
present three new X-ray crystal structures of apo-GDF8,
apo-GDF11, and GDF11 in complex with follistatin 288
(FS288). These structures, including an additional re-
cently solved apo-GDF11 crystal structure [46], reveal
that differences between GDF11 and GDF8 cluster in
the type I receptor binding epitope. Intriguingly, our
structural analysis has revealed unique and alternate
conformations of both GDF8 and GDF11, suggesting
that both ligands are inherently flexible. GDF8/GDF11
chimeras, in which particular GDF11 residues are
substituted into the GDF8 sequence, show that increased
potency can be conferred to GDF8. Taken together, our
results demonstrate that, despite the high sequence
identity between mature GDF8 and GDF11, the ligands
indeed possess different signaling properties.
Results
GDF11 is a more potent ligand than GDF8
Recent reports have attributed unique in vivo properties
to GDF11 relative to GDF8 [20–23]. Therefore, we first
aimed to determine if signaling differences exist between
these two growth factors using HEK293 (Fig. 1b) and
HepG2 (Fig. 1c) cells stably or transiently transfected,
respectively, with the SMAD3-responsive (CAGA)12
luciferase reporter [47–51]. Side-by-side titration of
mammalian-derived (see “Methods”) ligands revealed
that GDF11 was more potent than GDF8 in both cell
lines (Fig. 1b and c; Additional file 1: Table S1). Remark-
ably, we determined that the half-maximal effective con-
centration 50 (EC50) values for GDF11 in HEK293 and
HepG2 cells were 0.08 nM and 3.4 nM, respectively,
compared to 0.48 nM and 5.4 nM for GDF8, respectively
(Fig. 1c; Additional file 1: Table S1). Interestingly, the
maximal SMAD3 response achieved by GDF11 was ~
fourfold higher compared to GDF8 in HepG2 cells
Walker et al. BMC Biology  (2017) 15:19 Page 2 of 22
Fig. 1 (See legend on next page.)
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(Fig. 1c; Additional file 1: Table S1), suggesting that
there may be differences in ligand potency and/or in the
repertoire of receptors and their relative utilization. Fur-
thermore, we found that GDF11 (EC50 0.03 nM) more
potently stimulated the release of follicle-stimulating
hormone (FSH) than GDF8 (EC50 0.08 nM) in murine
LβT2 pituitary gonadotrope cells (Fig. 1d; Additional file 1:
Table S1). Finally, GDF11 activated SMAD3 with ~ a seven-
fold lower EC50 compared to GDF8 (6.5 nM versus 45.7
nM, respectively) in A204 cells transfected with the
(CAGA)12 luciferase reporter (Ravindra Kumar, per-
sonal communication). These results are consistent
with previous reports, which likewise indicated that
GDF11 is a more potent activator of SMAD3-
dependent signaling than GDF8 [16, 44]. Note that
ligands from different sources were utilized and were
directly compared using the SMAD3-responsive
(CAGA)12 luciferase reporter assay (Additional file 2:
Figure S1). For clarity, we have indicated the ligand
sources utilized for each study in the figure legends.
Given that GDF11 stimulated greater SMAD3 activa-
tion in a concentration-dependent fashion compared to
GDF8, we wanted to determine if this difference was
maintained when we performed a pulse-chase exposure
to each ligand (Fig. 1e and f; Additional file 3: Figure S2).
To examine this, we performed two separate experi-
ments. In the first, we treated HEK293 cells with GDF8
or GDF11 at three different concentrations (25, 125,
and 620 pM) for the indicated times (5–180 min), after
which the culture medium was removed and replaced
with ligand-free culture medium for the duration of the
experiment. At 24 h (1440 min), the cells were lysed
and assayed for SMAD3-dependent luciferase activity
(Fig. 1e; Additional file 3: Figure S2). GDF11 elicited a
stronger response compared to GDF8 in both a concen-
tration- and a time-dependent manner. In fact, at lower
concentrations and exposure times, treatment with
GDF11, but not GDF8, resulted in productive signaling
(25 pM, Fig. 1e). A second experiment was performed
where the cells were treated for the indicated time (60–
1440 min) and immediately assayed for activity (Fig. 1f;
Additional file 3: Figure S2). Interestingly, at the lower
concentration (25 pM; Fig. 1f), we observed a significant
difference in SMAD3 activation compared to GDF8 at
most time points. These differences were less pronounced
or non-existent at higher concentrations (Fig. 1f; Add-
itional file 3: Figure S2). Together, these results indicate
that the cellular response to mature GDF8 and GDF11
can be significantly different depending on the con-
centration and duration of exposure.
Modulation of GDF8 and GDF11 activity by known
extracellular antagonists
Like many TGFβ ligands, extracellular antagonists
modulate GDF8 and GDF11 signaling. Here, we deter-
mined if there were differences in the effectiveness of
the known antagonists FS288, FSTL3, GASP1, and
GASP2 to inhibit GDF8 or GDF11 using our HEK293
(CAGA)12 luciferase assay. FS288 and GASP1 similarly
inhibited GDF8 or GDF11 (Fig. 2a and c and Table 1).
However, FSTL3 and GASP2 (Fig. 2b and d and Table 1)
more potently inhibited the actions of GDF8 relative to
GDF11 (Table 1). Curiously, inhibition by FSTL3 for
GDF11 revealed a more negative Hill slope compared to
GDF8, suggesting that, while they are both potently
inhibited, the binding interactions between the ligands
and antagonists may not be identical.
Structure of GDF11 bound to FS288
The complex of the GDF11 dimer bound to two mole-
cules of FS288 was resolved using X-ray crystallography
to 2.35 Å (Fig. 3a and Table 2). This is the first structure
of GDF11 bound to a known antagonist. Similar to pre-
vious ligand:follistatin structures [52–54], two molecules
(See figure on previous page.)
Fig. 1 GDF11 is a more potent ligand than GDF8. a Overview of the well-established canonical activin A, activin B, GDF8, GDF11, and TGFβ receptor
utilization and downstream SMAD pathway. b, c, d Potency differences between GDF8 and GDF11. Luciferase reporter gene assay ((CAGA)12 promoter)
following titration of GDF8 (blue) and GDF11 (orange) ligands in HEK293 (b) and HepG2 (c) cells. Luciferase activity was assessed 18–24 h post ligand
treatment. The black arrows in (b) indicate the ligand concentrations utilized in panels e and f. In d, mouse gonadotrope (LβT2) cells were treated with
increasing doses of GDF8 (blue) or GDF11 (orange). Follicle-stimulating hormone (FSH) release was measured 24 h later, as previously described [92].
Refer to Additional file 1: Table S1 for a corresponding analysis of the activation curves. e Short exposure to GDF11 results in a significantly enhanced
SMAD3-dependent response compared to GDF8. The experimental design (left) is such that the ligand was added to HEK293 cells stably transfected
with the (CAGA)12 promoter driving the luciferase gene for the indicated time followed by replacement of media without ligand. Activity was
measured 24 h after initial treatment. Cells were treated with GDF8 or GDF11 at a ligand concentration of 25 pM (middle) and 125 pM (right).
f Time-dependent differences in the SMAD3 activation by GDF8 and GDF11. Similar experimental design (left) as in e, but instead cells were
lysed and assessed for luciferase activity at the indicated time of ligand treatment. Cells were treated with GDF8 or GDF11 at a ligand concentration
of 25 pM (middle) and 125 pM (right). Data information: In b, c and e, f, data are presented as fold activation above background (0 nM ligand
concentration). Each concentration was performed in triplicate and shown as the mean ± standard error of the mean (SEM) of three independent
experiments. In d, data are presented as fold FSH release above background (0 nM ligand concentrations). Each concentration was performed in triplicate
and shown as the mean ± SEM of one experiment; data shown are representative of 10 independent experiments. In e, f, curves were compared using
two-way ANOVA with Bonferroni correction (*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001). Ligand sources: for b, e, f, gift from Acceleron Pharma; for
c, d, purchased from R&D Systems; Cat. no. 788-G8-CF and Cat. no. 1958-GD-010-CF)
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of FS288 bind symmetrically to wrap around the GDF11
dimer occluding both type II and type I receptor binding
sites. As expected, follistatin domains 1 (D1) and D2
overlap with the type II binding epitope, whereas the fol-
listatin N-terminal domain (ND) occupies the type I
binding slot. The overall structure of GDF11:FS288 is
highly similar to that of the GDF8:FS288 complex
(Fig. 3a; overall root-mean-square deviation (RMSD) =
0.657 Å). Nonetheless, the structure of GDF11:FS288 re-
veals minor changes in the positioning of residues in the
helix of ND (Fig. 3a). For example, F47 of FS288 is
pushed inward to accommodate the larger side chain of
M50 in GDF11 versus V50 in GDF8 (Fig. 3a). This is
consistent with other ligand:FS structures, showing that
the ND helix is quite plastic in its “molding” to accom-
modate ligand differences at the type I interface [47, 48,
52–55]. As observed in previous ligand:FS structures
[52–54], the ND from one molecule interacts with D3
from the other follistatin in a head-to-tail fashion. Simi-
lar to GDF8:FS288 [54], the electrostatic surface poten-
tial of GDF11:FS288 depicts a large, continuous
electropositive surface on one side of the complex. This
is formed by the combination of the heparin binding
motif of the two FS molecules with positively charged
residues of GDF11 (Fig. 3b) [54]. As such, the
GDF11:FS288 complex has increased affinity for heparin
as compared to FS288 alone, and slightly stronger affin-
ity than GDF8:FS288 (Fig. 3c) [54, 56–59].
GDF8 and GDF11 structural differences: follistatin-bound
versus apo states
Initial investigation of the sequence alignment between
GDF8 and GDF11 mature domains did not provide a
clear explanation for why GDF11 is more potent than
GDF8 (Fig. 4a). In other words, there did not appear to
be major amino acid differences (i.e., charge reversals,
inclusions/deletions, etc.) between the two ligands that
would indicate significant differences in how they
would interact with binding partners or receptors.
However, when the differences between GDF8 and
GDF11 were plotted on the structure, we saw that the
Fig. 2 Inhibition of GDF8 and GDF11 by known antagonists. a, b, c,
d Luciferase reporter assays showing the inhibitory activity following
titration of FS288 (a), FSTL3 (b), GASP1 (c), and GASP2 (d) against a
constant concentration (0.62 nM, dashed bar) of GDF8 (blue) or
GDF11 (orange) in HEK293 (CAGA)12 cells. Refer to Table 1 for a
corresponding analysis of the inhibition curves. Data information: In
a–d, data are presented as fraction activation (ligand response at
antagonist concentration/ligand response at 0 nM antagonist). Each
concentration was performed in triplicate and shown as the mean
± SEM of two to three independent experiments. Data from
independent experiments were combined and fit to non-linear
regression with a variable slope. Ligand source: gift from
Acceleron Pharma
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majority are found near the type I receptor interface
(Fig. 4b; Additional file 4: Figure S3). Therefore, to
determine if there were any unique structural conse-
quences of these amino acid differences, we made a
more thorough examination of the X-ray crystal
structures of mature GDF8 and GDF11 in the
follistatin-bound and apo states.
Superposition of the mature ligands from their re-
spective FS288 complex structures did not reveal any
major structural differences in the type II interface
Table 1 Analysis of known antagonists to GDF8 and GDF11 by luciferase reporter assay
Ligand Antagonist IC50 (nM) IC50 (nM) 95% CI
a Log[IC50(M)] ± SEM
b Hill slope Hill slope 95% CI
GDF8 FS288 0.2 0.21 to 0.23 −9.7 ± 0.01 −4.31 −5.17 to −3.43
GDF11 0.3 0.27 to 0.34 −9.5 ± 0.03 −4.77 −6.73 to −2.81
GDF8 FSTL3 1.2 1.08 to 1.30 −8.9 ± 0.02 −1.93 −2.19 to −1.68
GDF11 4.0 3.72 to 4.35 −8.4 ± 0.02 −5.41 −6.79 to −4.02
GDF8 GASP1 0.2 0.25 to 0.24 −9.6 ± 0.01 −4.47 −4.90 to −4.03
GDF11 0.3 0.29 to 0.39 −9.1 ± 0.02 −4.34 −5.49 to −3.20
GDF8 GASP2 4.1 3.31 to 5.07 −8.4 ± 0.05 −1.64 −2.15 to −1.14
GDF11 18.3 14.98 to 22.46 −7.7 ± 0.04 −1.67 −2.18 to −1.16
a CI confidence interval
b SEM standard error of the mean
Fig. 3 The structure of the GDF11:FS288 complex. a Comparison of the GDF11:FS288 (top) and GDF8:FS288 (bottom; Protein Data Bank (PDB)
3HH2; [54]) structures. The inset shows the differences between the interaction of the FSND helix and the ligand type I receptor epitope.
Recombinant human GDF11 was obtained from Acceleron Pharma for resolution of this crystal structure. b Isoelectric surface representation of
the GDF11:FS288 (left) and GDF8:FS288 (right) structures. Surfaces are colored blue (positive) and red (negative) on a scale of –5 to 5 kbT/ec using
the APBS plugin [97] for PyMol. c Heparin affinity analysis of FS288 alone, GDF11:FS288, and GDF8:FS288 complexes. GDF11:FS288 complex has
higher affinity for heparin than FS288 alone indicated by elution at a higher ionic strength. Purified proteins and complexes (100 μg) were
applied to a heparin column and eluted with a linear sodium chloride (NaCl) gradient. The approximate NaCl concentration for protein elution is
shown at the peak maxima. Ligand source: gift from Acceleron Pharma
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(convex surface) of the ligand. However, examination of
the type I interface revealed two unique interactions in
the wrist of GDF11 compared to GDF8 (Fig. 4a and b).
The wrist region is known to be critically important for
dictating ligand type I receptor affinity and specificity
[38, 54, 60]. First, superposition of the ligands showed
that Y55A of GDF11 was shifted by ~1.3 Å inward to-
ward the N-terminal side of the wrist helix on the adja-
cent monomer. This was facilitated by the lack of a side
chain in G100B of GDF11 (for clarity, the subscript is
used to differentiate one ligand monomer from another;
for reference, see Fig. 5a). In GDF8, the corresponding
residue is A100B where the methyl side chain sterically
occludes Y55A. This difference allows Y55A to more in-
timately interact with the opposing chain and facilitates
additional hydrophobic interactions with M79B and the
aliphatic side chain of K54A. The second unique feature
of GDF11 is the formation of an additional hydrogen
bond between the backbone (Y49A) of the pre-helix loop
and Q62A located on the C-terminal side of the wrist
Table 2 X-ray data collection and refinement statistics (molecular replacement)
GDF11:FS288 (native)a apo-GDF8 (native)a apo-GDF11 (native)a
Data collection
Space group P 21 21 21 P 21 21 21 P 32 2 1
Unit cell dimension
a, b, c (Å) 56.0, 59.1, 288.5 29.6, 77.7, 119.5 65.2, 65.2, 101.9
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 120
Wavelength (Å) 1.03321 0.97856 1.10537
Resolution (Å) 2.35 (2.43-2.35) 2.25 (2.32-2.25) 1.9 (1.94-1.9)
Rmerge 0.076 (0.519) 0.079 (1.102) 0.069 (0.706)
Rpim 0.046 (0.311) 0.032 (0.436) 0.032 (0.316)
Mn (I/σI)b 10.0 (2.6) 18.2 (2.0) 10.4 (2.0)
CC1/2
c 0.74 0.72 0.996
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0)
Redundancy 3.7 (3.8) 7.1 (7.3) 5.8 (5.9)
Refinement
Resolution (Å) 41.28-2.35 36.96-2.25 49.37-1.9
No. reflections 40,978 (4,031) 13,776 (1,912) 20,166 (2,642)
Rwork (%), Rfree
d (%) 20.3/24.7 23.4/27.7 21.7/25.8
No. of atoms (molecules)
Protein 6047 (784) 1443 (187) 1395 (181)




B-factors (average, Å2) 60.0 65.1 60.3
RMS deviations
Bond lengths (Å) 0.005 0.003 0.007
Bond angles (°) 0.960 0.951 0.853
Ramachandran plot
Favored (%) 97.15 94.44 97.63
Allowed (%) 2.59 5.56 2.37
Outliers (%) 0.26 0.0 0.0
Clashscoree 4.18 6.83 3.33
aValues in parentheses are for highest resolution shell
bMn(I/σI) is defined as <merged < Ih >/sd (< Ih >) > ≈ signal/noise
cCC1/2 for highest resolution shell
dRfree calculated from 5% of initial total number of reflections
eDetermined by MolProbity
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helix (Fig. 4b). In GDF8, the corresponding residue is
H62A and does not interact with the pre-helix loop in
the FS288-bound GDF8 crystal structure (Fig. 4b). In
fact, H62A does not interact with the pre-helix loop in
additional crystal structures of GDF8 bound to either
FSTL3 [47] or a neutralizing antibody (Fig. 5a) [61].
Thus, amino acid differences between GDF8 and GDF11
impose unique intramolecular contacts in GDF11 that
are not present in GDF8. Given that these changes occur
at the type I interface, it is intriguing to speculate that
they could contribute to differences in ligand activity.
However, we cannot exclude the possibility that these
newly identified interactions are a result of binding to
FS288. To explore this possibility, we examined the X-
ray crystal structures of apo-GDF8 and apo-GDF11 [46].
We resolved the structure of apo-GDF8 to 2.25 Å
(Fig. 5a and Table 2) and the apo-GDF11 structure to
1.90 Å (Fig. 5b, bottom; Table 2) using X-ray crystallog-
raphy, thus allowing a direct comparison to the recently
published apo-GDF11 structure (Fig. 5b, middle)
[46]. Unexpectedly, resolution of the apo-GDF8
structure revealed a unique conformation such that
the fingertips of each monomer are positioned prox-
imally in a “closed” conformation compared to the
classical distal positioning or “open” conformation
observed for many ligands, including structures of
FS-bound GDF8 (Fig. 5a, top) [38, 47, 54]. While the
structure of apo-GDF8 adopted an unexpected
“closed” conformation, a similar conformation has
been observed for activin A when in complex with
ActRIIB [62]. In both cases, the wrist region is disor-
dered and not resolved in the crystal structure
(Fig. 5a). Our new apo-GDF11 structure, solved
under similar crystallization conditions as apo-GDF8,
Fig. 4 Sequence alignment and structural comparison of GDF8 and GDF11 in their FS288-bound state. a Sequence alignment of mature GDF8
and GDF11. Secondary structure for each ligand in the FS288-bound form is shown above and below the GDF8 and GDF11 sequences, respectively,
where arrows represent β-sheet and cylinders represent α-helix. Cysteines are highlighted in yellow, and residues that are different between GDF8 and
GDF11 are highlighted in blue. Solid black lines joining two cysteines indicate intramolecular disulfide bonds. The dotted black line indicates the cysteine
responsible for the intermolecular disulfide bond. b Distribution of the amino acid differences between GDF8 and GDF11. GDF11 is shown as ribbon,
and non-identical amino acids are shown as orange spheres. Symmetrical type I and type II interfaces are depicted with blue and yellow lines (left). Insets
represent zoomed-in views depicting the molecular differences between FS288-bound GDF8 (blue) and FS288-bound GDF11 (orange) in the vicinity of
the type I receptor binding interface. The arrow points to the hydrogen bond (dotted line) in the FS288-bound GDF11 between Q62 and
carbonyl oxygen of Y49 (middle)
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adopted an exaggerated “open” conformation such
that the fingers extend past the horizontal plane
(Fig. 5b). This conformation shares a similar exag-
gerated “open” conformation to the crystal structure
of GDF8 bound to a neutralizing antibody (Fig. 5a,
bottom) [61]. However, the wrist region in our apo-
GDF11 structure is also disordered and not resolved
in the crystal structure, similar to apo-GDF8 (Fig. 5b,
bottom). The previously published apo-GDF11 crys-
tal structure adopts the classic “open” conformation
with an ordered wrist helix that includes the additional in-
terchain hydrogen bond between Q62A and the pre-helix
loop observed in the FS288-bound GDF11 crystal struc-
ture. Taken together, crystallization of both GDF8 and
GDF11 in their apo states reveals intrinsic structural flexi-
bility in these ligands.
Fig. 5 Structural comparison of GDF8 and GDF11 in FS288-bound and apo-conformations reveal ligand flexibility. Cartoon diagrams of the bound
and apo states of GDF8 (a) and GDF11 (b). Each monomer is colored independently to highlight the differences in conformation. Superposition
of each conformation using monomerB (gray) is shown on the left. Protein Data Bank (PDB) IDs for bound ligands (FS288-bound GDF8 = 3HH2
[54]; antibody-bound GDF8 = 5F3B [61]; GDF11 = 5JHW) and apo ligands (GDF8 = 5JI1; GDF11 = 5E4G [46]; GDF11 = 5UHM). Resolution of apo-GDF8
was determined from recombinant human GDF8 produced and purified as previously described [54]. Resolution of FS288-bound and apo-GDF11 was
determined from recombinant human GDF11 produced and purified by Acceleron Pharma
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GDF11 signals more effectively through type I receptors
than GDF8
To better understand the potency differences between
GDF11 and GDF8, we compared their receptor binding
affinities and utilization. Given that the structural differ-
ences between GDF11 and GDF8 are positioned at the
type I receptor interface, we hypothesized that potency
differences are likely through differences in type I inter-
actions. In order to rule out potential differences in type
II receptor binding, we first compared the inhibitory
potential (i.e., dominant negative effect) of the soluble
receptors, ActRIIB extracellular domain (ECD) and Fc-
ActRIIB-ECD using our HEK293 (CAGA)12 luciferase
assay (Fig. 6 and Table 3). We found no difference in the
IC50 value for ActRIIB-ECD between GDF8 and GDF11
(12.4 nM versus 14.0 nM, respectively), whereas Fc-
ActRIIB-ECD was ~ threefold more potent in inhibiting
GDF8 (IC50 = 3.0 nM) than GDF11 (IC50 = 10.3 nM;
Fig. 6a and b; Table 3). While the calculated Hill slope
for the ActRIIB-ECD was similar for GDF8 and GDF11,
we observed a more negative Hill slope for the inhibition
of GDF11 by the Fc-ActRIIB-ECD compared to GDF8,
similar to our earlier results showing a more negative
Hill slope when GDF11 was antagonized by FS288,
FSTL3, and GASP1 (Fig. 2 and Table 1).
Next, we determined if GDF8 and GDF11 signal
through similar type I receptors. Numerous studies have
shown that GDF8 and GDF11 utilize the type I receptors
ALK4 and ALK5 [6–8]. In addition, GDF11 can signal
through ALK7 [8], although it is unclear if GDF8 also
utilizes this receptor. To our knowledge, a study directly
comparing signaling by both ligands via the three recep-
tors has not been reported. Therefore, we assessed the
relative (CAGA)12 luciferase reporter response to GDF8
or GDF11 following transient expression of individual
type I receptors in RIB L17 cells (Fig. 6c and d). This cell
line lacks ALK5 expression and expresses low levels of
ALK4 [7, 54, 63]. The level of ALK7 expression in these
cells has not been reported. As expected, activin A ro-
bustly signaled in cells transfected with ALK4 [63, 64],
activin B signaled through both ALK4 and ALK7 [65,
66], and TGFβ3 specifically signaled through ALK5
(Fig. 6c) [67, 68]. Consistent with previous reports,
GDF8 and GDF11 readily signaled through ALK4 and
ALK5 [6–8, 54]. Additionally, we confirmed that GDF11
signaled through ALK7 (Fig. 6c and d) [8]. Strikingly,
GDF11 induced greater reporter responses than GDF8
via ALK4, ALK5, or ALK7 (Fig. 6c and d). We should
note that activin A, activin B, GDF11, and to a lesser ex-
tent GDF8, stimulated some reporter activity in the ab-
sence of exogenous receptors, suggesting low levels of
endogenous ALK4 and ALK7 expression by these cells
(Fig. 6c). Consistent with this idea, activin B, GDF8, and
GDF11 induction of reporter activity was completely
blocked by addition of the ALK4/5/7 small molecule
inhibitor SB431542 (Fig. 6d) [69–72]. Importantly,
signaling could be rescued by transfection of an
SB431542-resistant form (S270T) of human ALK7
(Fig. 6d), confirming that all three ligands can signal via
ALK7 with relative potencies of activin B > GDF11 >
GDF8. Collectively, our results indicate that GDF11 can
generate a greater SMAD3-dependent signal compared
to GDF8 through all three type I receptors.
Given that type I receptor expression is not ubiqui-
tous in all cells, we next wanted to determine if differ-
ences in ALK4/5/7 combinations would further
distinguish or normalize response differences between
GDF8 and GDF11. Different receptor combinations
modestly enhanced signaling relative to individual re-
ceptors (Fig. 6c). Interestingly, when ALK4 and ALK5
were co-transfected, there was no statistically signifi-
cant difference in response to GDF8 and GDF11 (at the
concentration tested), in contrast to when either recep-
tor was expressed alone (Fig. 6c). Co-transfection of
ALK4 and ALK7 resulted in a more robust response to
GDF11 over GDF8. Taken together, these results fur-
ther suggest that ligand sensitivity can be driven, in
part, by the receptor(s) expressed on a particular cell
type, thereby providing a possible avenue by which cells
may discriminate between highly similar ligands, such
as GDF8 and GDF11.
Structural studies describing the interaction between
the type I receptors and the activin/inhibin subclass are
lacking, predominantly due to the inability to generate
recombinant receptors whose folding and biological ac-
tivity can be confirmed unequivocally. While this barrier
remains unresolved for ALK4 and ALK7, we can reliably
study the interactions between ligands and the ALK5-
ECD [73, 74]. We tested binding of GDF8 and GDF11 to
recombinant ALK5-ECD in the absence or presence of
ActRIIB-ECD using Native-PAGE and surface plasmon
resonance (SPR; Fig. 7). Neither mature GDF8 nor
GDF11 alone were readily resolved using Native-PAGE
(lanes 1 and 4 in Fig. 7a). However, addition of
ActRIIB-ECD to either ligand resulted in a mobility
shift compared to ActRIIB-ECD alone, indicative of
complex formation between the ligand and type II re-
ceptor (compare lanes 5 and 6 in Fig. 7a). Mixing the li-
gands with ALK5-ECD alone did not result in a
detectable ALK5-ECD-ligand complex (lanes 2 and 3 in
Fig. 7a). However, when we co-incubated either ligand
with a constant amount of ActRIIB-ECD followed by ti-
tration with ALK5-ECD, we observed a noticeable shift
in the migration pattern for GDF11, especially apparent
at excess molar ratios of ALK5-ECD. Under similar
conditions, little to no change was observed with GDF8
(compare lanes 6 through 10 in Fig. 7a). Although high
concentrations were required, these results suggest that
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a low-affinity ternary complex composed of GDF11:Ac-
tRIIB:ALK5 was more readily formed than the corre-
sponding complex with GDF8.
To clarify these results, we attempted to detect dir-
ect binding of either ligand to ALK5-ECD, Fc-ALK5-
ECD, and Fc-ActRIIB using SPR (Fig. 7b; Additional
file 5: Figure S4). In this experiment, the receptor was
immobilized on the SPR biosensor chip with standard
amine coupling or captured using Protein A. As
expected, both ligands readily bound the Fc-ActRIIB-
ECD (Additional file 5: Figure S4D) [6–8]. Qualita-
tively, GDF11 interacted with both ALK5-ECD and
Fc-ALK5-ECD in a dose-dependent manner and ex-
hibited a fast association and rapid dissociation
(Fig. 7b; Additional file 5: Figure S4A–C, E, F). In
contrast, GDF8 did not bind to ALK5-ECD or Fc-
ALK5-ECD in a dose-dependent fashion (Fig. 7b;
Additional file 5: Figure S4E, F). Given that ALK5
binding to TGFβ is significantly enhanced through a
cooperative interaction with TβRII [73, 74], we specu-
lated that ActRIIB might improve GDF8 or GDF11
binding to ALK5-ECD. Interestingly, co-injection of
Fig. 6 Enhanced type I receptor utilization by GDF11 compared to
GDF8. a, b, Luciferase reporter assays showing the inhibitory activity
following titration of ActRIIB-ECD (a), and Fc-ActRIIB-ECD (b) against
a constant concentration (0.62 nM, dashed bar) of GDF8 (blue) or
GDF11 (orange) in HEK293 (CAGA)12 cells. Refer to Table 3 for a
corresponding analysis of the inhibition curves. c Differences in
type I receptor utilization by GDF11 following transient transfection
of a single type I receptor (ALK4, ALK5, or ALK7) or a combination
of type I receptors (ALK4/ALK5, ALK4/ALK7, ALK5/ALK7, or ALK4/
ALK5/ALK7). RIB L17 cells were co-transfected with 1.25 ng of the
individual receptor DNA alone or various receptor DNA combinations
(1.25 ng each receptor) and 2.5 ng (CAGA)12 promoter plasmid driving
the luciferase gene. Purified recombinant ligands were added 12 h
post transfection. Cells were then lysed and assessed for luciferase
activity 8 h post ligand treatment. d Treatment of RIB L17 cells with
DMSO or the type I receptor small molecule inhibitor SB431542
following transfection of empty vector (EV) or ALK7 S270T. RIB L17
cells were co-transfected with 1.25 ng of the individual receptor
DNA and 2.5 ng (CAGA)12 promoter plasmid driving the luciferase
gene. Purified recombinant ligands were added 12 h post transfection.
Cells were then lysed and assessed for luciferase activity 8 h post
ligand treatment. Data information: In a, b, data are presented as
fraction activation (ligand response at antagonist concentration/ligand
response at 0 nM antagonist). Each concentration was performed in
triplicate and shown as the mean ± SEM of two independent
experiments. Data from independent experiments were combined
and fit to non-linear regression with a variable slope. In c, d, data are
presented as fold activation defined as the total activation from each
ligand compared to cells only transfected with the (CAGA)12 reporter
construct. Each bar is the mean ± SEM. A representative experiment is
shown of at least two independent experiments in which each
concentration was performed in duplicate or triplicate. Only comparisons
between GDF8 and GDF11 were made. *P ≤ 0.05 and **P ≤ 0.001
(Student’s t test). Ligand sources: GDF8 and GDF11, gift from Acceleron
Pharma; Activin A, Activin B, and TGFβ3, produced and purified as
described in “Methods”
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ActRIIB-ECD with GDF11 did not appear to alter the as-
sociation or dissociation with ALK5-ECD compared to
GDF11 alone (Fig. 7b right two panels; Additional file 5:
Figure S4B, C). However, we did observe a detectable
improvement in binding of GDF8 to ALK5-ECD in the
presence of ActRIIB-ECD (Fig. 7b; Additional file 5:
Figure S4B, C). These results suggest that GDF11 bind-
ing to ALK5 is likely more favorable compared to
GDF8. However, it is clear that additional experiments
will be necessary to fully resolve the interactions be-
tween these ligands and their cognate type I receptors.
Substitution of GDF11-like residues into GDF8 enhances
ligand activity
To determine which residues are important for confer-
ring enhanced activity to GDF11, we generated a num-
ber of GDF8/GDF11 chimera constructs. Site-directed
mutagenesis was performed on the full-length human
GDF8 to introduce GDF11-like substitutions (for refer-
ence, see Fig. 4a). We compared the activity of the
chimeras to wild-type (wt) GDF8 by transient co-
transfection of the constructs with tolloid-like 2 (TLL2)
and furin using HEK293 (CAGA)12 luciferase cells
(Fig. 8; Additional file 6: Figure S5). We focused our
efforts on the regions showing the most divergence be-
tween GDF8 and GDF11, specifically the type I inter-
face consisting of the pre-helix loop and wrist (for
reference, see Additional file 4: Figure S3). Interestingly,
transient expression of a number of chimeric mutants
revealed a significant gain in activity (Fig. 8a). The in-
creased activity was observed at nearly every concentra-
tion (25, 50, and 100 ng DNA) tested (Fig. 8a), with
differences between the chimeric mutants and wt GDF8
more pronounced at lower concentrations (25 ng ver-
sus 100 ng; Fig. 8a). Thus, incorporation of GDF11-like
residues into GDF8 can increase ligand potency. Con-
sistent with our overall hypothesis, we found that full
substitution (chimera 12, GDF8pro/GDF11 mature) of
all different residues between mature GDF8 and GDF11
resulted in a very potent ligand compared to wt GDF8,
particularly at lower concentrations (Fig. 8a). Remark-
ably, a significant gain in activity was observed in the
chimeras that incorporated the GDF11 residues, Q62
and G100 (e.g., chimera 11 in Fig. 8a), which were
shown in the structure to form additional, stabilizing
interactions at the ligand dimer interface (Fig. 8a).
To rule out that activity differences were attributed to
differences in the relative amounts of protein expression,
we produced and purified wt (wt GDF8 prodomain:ma-
ture GDF8) and selected mutant latent complexes (wt
GDF8 prodomain:mature GDF8/GDF11 chimera). To
determine their specific activity relative to wt GDF8
(Fig. 8b and c), we used two methods known to activate
the latent complex: acid activation (treatment with HCl
to pH 2.5; [24]) and activation with a member of the
TLD family, such as tolloid-like 2 (TLL2) [75]. Overall,
our results from treatment with purified protein were
consistent with the results from transient transfection
(Fig. 8b and c). As expected, little to no luciferase activ-
ity was detected in cells treated with the latent com-
plexes unless they were acid activated (Fig. 8b) or
applied to cells transfected with TLL2 (Fig. 8c). In
addition, we performed the experiments in the presence
of GASP1, a specific antagonist of GDF8 and GDF11
[10, 42, 76], to confirm that the signal was specific to wt
GDF8 or GDF8/GDF11 chimeras (Fig. 8b and c). Both
activation methods revealed similar findings with the ex-
ception of the acid-activated empty vector sample (EV;
conditioned medium from empty vector transfected and
mock purified). The acid-activated EV sample showed a
significant response that could not be attenuated with
GASP1 (Fig. 8b), indicating possible contamination by
additional ligands or pH-dependent artifacts. Despite
this possibility, most of the signal with GDF8 or GDF8/
GDF11 chimeras was attenuated by GASP1, suggesting
that the majority of the signal was specific to the ligands
added. Moreover, the higher background signal was not
observed in the TLL2 experiment (Fig. 8c). Together,
these data support the conclusions that mature GDF11
is more active than GDF8 and that GDF8 activity can be
enhanced through substitution of specific residues from
GDF11.
GDF11 is a more potent inducer than GDF8 of
phosphorylated SMAD2/3 in mouse primary skeletal
myoblasts in vitro and the mouse myocardium in vivo
Since we have shown that GDF11 is more potent than
GDF8 in multiple cell lines, we next sought to determine
Table 3 Analysis of ActRIIB-ECD on GDF8 and GDF11 activity by luciferase reporter assay
Ligand Receptor IC50 (nM) IC50 (nM) 95% CI
a Log[IC50(M)] ± SEM
b Hill slope Hill slope 95% CI
GDF8 ActRIIB-ECDc 12.4 12.24 to 13.66 −7.9 ± 0.02 −1.73 −1.99 to −1.47
GDF11 13.0 12.61 to 15.46 −7.9 ± 0.02 −1.57 −1.79 to −1.35
GDF8 Fc-ActRIIB-ECD 3.0 2.60 to 3.38 −8.5 ± 0.03 −2.24 −2.82 to −1.65
GDF11 10.3 9.40 to 11.125 −8.0 ± 0.02 −8.05 −10.46 to −5.63
aCI confidence interval
bSEM standard error of the mean
cECD extracellular domain
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if similar differences in potency could be seen in primary
cells. Consistent with a previous report [16], western
analysis of cultured myoblasts treated with mature
GDF8 or GDF11 at a range of concentrations showed
robust, dose-dependent induction of phosphorylated
SMAD2/3 (pSMAD2/3) compared to untreated cultures
(Fig. 9a). Further, GDF11 treatment elicited a signifi-
cantly greater induction of pSMAD2/3 compared to
equivalent concentrations of GDF8 (Fig. 9a and b).
To determine if similar potency differences between
GDF11 and GDF8 may also occur in vivo, we next ex-
amined SMAD2 phosphorylation (pSMAD2) in the
mouse myocardium following intravenous (tail vein) in-
jection of various doses of GDF8 and GDF11 (Fig. 10).
pSMAD2 levels were significantly increased in the myo-
cardium 1 h after injection of 0.5 mg/kg of GDF8 or
GDF11 (Fig. 10a and c). At equivalent doses, GDF11
stimulated significantly more pSMAD2 than GDF8
(Fig. 10a and c). In fact, nearly eightfold more GDF8
than GDF11 was required to achieve similar levels of
pSMAD2 (Fig. 10b and d). These data suggest that, de-
pending on dose, intravenous GDF8 or GDF11 can re-
sult in a significantly different SMAD2/3-dependent
response in the myocardium.
Discussion
Previous studies indicate that GDF8 and GDF11 have
both divergent and overlapping roles in developmental
processes and tissue maintenance in adult animals
(reviewed in [1–5]). While the role of GDF11 during de-
velopment is well defined, its role in the adult remains
poorly understood. However, recent evidence suggests
that GDF11 is an important circulating factor that de-
clines with age and exogenous treatment with GDF11
can reverse age-related effects including reducing car-
diac hypertrophy [22, 23], improving skeletal muscle re-
generation [21], and promoting neurogenesis [20].
However, other studies have contradicted certain aspects
of these claims, fueling significant controversy on the
functional similarities and differences between GDF11
and GDF8 [16, 17, 43, 44]. Controversy notwithstanding,
in this study, we investigated the signaling activity and
structural features of the mature GDF11 and GDF8
ligands.
At the outset of our studies, we made the unexpected
observation that GDF11 is a more potent signaling lig-
and than GDF8. This observation was consistently and
reproducibly observed across multiple laboratories, using
different ligand preparations, in multiple cell lines and
cultured primary cells, and recapitulated in vivo in the
mouse myocardium. The current dogma in the literature
suggests that there are no differences in the signaling
potencies of GDF8 and GDF11 and that the ligands have
identical signaling properties [16, 17, 43, 44]. Our results
Fig. 7 Binding of GDF11 to the type I receptor ALK5. a Basic
Native-PAGE (12%) of GDF8 (top) and GDF11 (bottom) ligand, receptor,
and ligand:receptor complexes. To test for ligand-receptor complex
formation, receptors were first diluted into 20 mM HEPES pH 7.4
followed by addition of the ligand. The ligand:receptor mixtures were
held at room temperature (25 °C) for 15 min before being loaded and
run in the gel. Amount loaded for each protein: ligand (high conc.; lane 1),
ALK5-ECD (lane 2), ligand+ALK5-ECD (lane 3), ActRIIB-ECD (lane 5) = 3 μg
each; ligand (low conc.; lane 4) = 1.5 μg; ligand + ActRIIB-ECD
(lane 6) = 1.5 μg ligand and 3 μg ActRIIB-ECD; for ALK5-ECD titration
(blue triangle; lanes 7–10) ligand = 1.5 μg, ActRIIB-ECD = 3 μg, and 1, 2,
4, or 8 μg ALK5-ECD. Proteins were visualized by colloidal Coomassie
stain. b Surface plasmon resonance (SPR) sensorgrams of GDF8 (left)
and GDF11 (right) binding to Fc-ALK5-ECD. Fc-ALK5-ECD was captured
by Protein A that was amine coupled to a CM5 chip. Serial dilutions
(500–15.265 nM) of each ligand alone (top) or in the presence (bottom)
of a twofold molar excess of ActRIIB-ECD were allowed to associate for
120 s at a 70 μL/min flow rate followed by a 280 s dissociation at 37 °C.
Sensorgrams were double referenced using an average of two 0 nM
ligand injections. Data information: Ligand sources: GDF8 and GDF11,
gift from Acceleron Pharma; Activin A, Activin B, and TGFβ3, produced
and purified as described in “Methods”
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are consistent with this idea, but only at the highest lig-
and concentrations examined. Interestingly, prior studies
also appeared to show that GDF11 is more potent or ac-
tive than GDF8 [16, 44], yet many conclusions from
these studies maintain the notion that GDF8 and GDF11
signal and function identically. The conclusion that
GDF8 and GDF11 are indistinguishable may derive from
the fact that subsequent comparisons were performed at
concentrations that were above the EC100 for both
ligands, thus resulting in identical transcriptional out-
comes. In fact, we show that at high concentrations of
GDF8 and GDF11, SMAD3-dependent readout is indis-
tinguishable under certain conditions (see early time
points in Fig. 1e and f). However, our data also reveal
that GDF11 can elicit a significant response under con-
ditions where GDF8 appears to have little to no activity.
These results show that the responses generated by
GDF8 and GDF11 are highly dependent on the
Fig. 8 Generation of GDF8/GDF11 chimeric ligand confers potency to GDF8. a Luciferase reporter gene assay ((CAGA)12 promoter) following
transient co-transfection of HEK293 cells with GDF8/GDF11 chimera constructs (25 ng, 50 ng, or 100 ng), furin (50 ng), and TLL2 (50 ng). All constructs
contain human wild-type GDF8 prodomain followed by human wild-type or mutated mature GDF8. 18–24 h post transfection, the culture media were
replaced with serum-free media and allowed to incubate for an additional 24 h, at which point the cells were lysed and measured for luciferase activity.
wt = GDF8; point mutations are indicated by number. For chimera number 12 (GDF8 pro/GDF11 mature), each non-identical residue between GDF8
and GDF11 was mutated to generate the equivalent wt GDF11 ligand. A surface representation of GDF8 dimer is shown. Each monomer is
colored independently (monomer A = blue; monomer B = gray). Non-identical residues are shown in orange. b, c Luciferase reporter gene
assay ((CAGA)12 promoter) following exogenous addition of purified empty vector, wt, or GDF8/GDF11 chimeric latent protein complexes
(see Additional file 6: Figure S5). The latent complexes (~1.5 ng mature ligand) were activated by treatment with acid (b; adjusted to pH 2.5 for 1 h
and then neutralized), or the HEK293 cells were transiently transfected with TLL2 prior to protein addition (c). AA acid activated, Not AA no acid
activation, Not AA + GASP1 no acid activation but complexes added to cells in the presence of 100 nM GASP1, AA + GASP1 acid activation
in the presence of 100 nM GASP1, EV empty vector transfected, EV + GASP1 empty vector transfected, but complexes added in the presence of 100
nM GASP1, TLL2 transfected with TLL2, TLL2 + GASP1 cells transfected with TLL2, complexes added in the presence of 100 nM GASP1. Data information:
In a, b, c, data are presented as a ratio of the fold activation (mutant/wt GDF8) where each was normalized to the response of empty vector control.
Each concentration was performed in duplicate or triplicate, and each bar is shown as the mean ± SEM from two to three independent experiments.
aP≤ 0.05, bP≤ 0.01, cP≤ 0.001, and ns = not significant (Student’s t test). Ligand sources: produced and purified as described in “Methods”
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concentrations of ligand and the available receptors, em-
phasizing that GDF8 and GDF11 are not equivalent. To
be clear, these data neither support nor refute claims
made by other groups regarding the functional outcomes
resulting from GDF8 or GDF11 signaling. Rather, they
demonstrate that the biochemical responses elicited by
GDF8 and GDF11 at equivalent concentrations are sig-
nificantly different under the conditions we tested. The
physiological relevance, if any, which may result from
potency differences, requires additional investigation.
Given the nearly identical sequence of their mature li-
gands, we were initially puzzled by the potency differ-
ences between GDF8 and GDF11, especially since most
of the changes are relatively conserved. Therefore, we
turned to X-ray crystallography to determine the struc-
tures of GDF11 in complex with FS288 in addition to
GDF8 and GDF11 in their apo forms. While this manu-
script was in preparation, an additional apo-GDF11
structure was resolved [46], thus providing the oppor-
tunity to compare multiple structures of each ligand in
their FS288-bound and apo states. As expected, the
overall structures of the ligands when bound to FS288
are highly similar with minor changes in the FSND helix
of FS288, a region previously shown to be able to ac-
commodate different ligands [47, 48, 52–55]. Compari-
son between GDF8 and GDF11 revealed that differences
cluster within and around the type I receptor binding
surface. In particular, differences are observed in resi-
dues within or bordering the wrist helix, an area import-
ant for type I receptor binding ([54]; reviewed in [38]).
To explore if these differences are the basis for in-
creased activity, we used a chimeric approach that intro-
duced GDF11-specific residues into GDF8. Apart from
the pre-helix loop, the two most prominent differences
Fig. 10 Intravenous injection of GDF11, but not GDF8, elicits robust
phosphorylation of SMAD2/3 in the mouse myocardium. a, b, c, d
Representative western blots (a, b) showing phosphorylated SMAD2
(pSMAD2), total SMAD2/3 (SMAD2/3), and GAPDH and corresponding
quantification (c, d) in the mouse myocardium 1 h post tail-vein
injection of saline, GDF8, or GDF11. a, c show a direct comparison in
the level of pSMAD2 in the myocardium following injection of
0.5 mg/kg GDF8 or GDF11 (n = 3 mice/treatment). b, d show that
nearly eightfold more GDF8 than GDF11 is required to achieve a
similar pSMAD2 response (saline n = 2 mice; GDF11 = 0.5 mg/kg n = 3
mice; GDF8 n = 1 mouse per dose). Data information: In c, d, data are
presented as a ratio of pSMAD2/total SMAD2/3. To obtain this ratio,
pSMAD2 or SMAD2/3 was first normalized to GAPDH. The ratio of this
quotient was then graphed. Data are presented as the mean ± SEM.
*P≤ 0.05 and ***P≤ 0.001 (Student’s t test). Ligand sources: PeproTech
Cat. no. 120-00 and Cat. no. 120-11
Fig. 9 Exogenous treatment of GDF11 potently activates SMAD2/3
in cultured primary skeletal muscle myoblasts. a, b Western blot (a)
and quantification (b) showing phosphorylated SMAD2/3 (pSMAD2/3),
total SMAD2/3 (tSMAD2/3), and GAPDH of cultured primary skeletal
muscle myoblasts following treatment with GDF8 or GDF11. Cells were
treated with a range of ligand concentrations (10, 50, and 250 ng) for
1 h, lysed, and probed for the indicated proteins. 20 μg total protein
loaded. Primary skeletal myoblasts were obtained from three different
animals (n = 3). Data information: In b, data are presented as a ratio
of pSMAD2/3 to total SMAD2/3. To obtain this ratio, pSMAD2/3 or
SMAD2/3 was first normalized to GAPDH. The ratio of this quotient
was then graphed. Data are presented as the mean ± SEM. *P≤ 0.05
and **P≤ 0.01 (Student’s t test). Ligand sources: PeproTech Cat. no.
120-00 and Cat. no. 120-11
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between the structures of GDF11 and GDF8 are located
at each end of the wrist helix and include GDF11 resi-
dues Q62 and G100. In both cases, substitution of the
individual GDF8 residues H62 and A100 with the
GDF11 residues Q62 and G100 resulted in increased ac-
tivity over wild-type GDF8. Moreover, combination of
these two mutations (H62Q/A100G) resulted in an add-
itional gain in activity over the single mutations alone,
suggesting an additive effect. In GDF11, these residues
appear to stabilize the dimer interface where an add-
itional hydrogen bond is formed between Q62 and the
backbone of the pre-helix loop. Thus, increased dimer
stability or stability of the interaction between the wrist
and pre-helix loop might be one explanation for the in-
creased ligand activity of GDF11, though we cannot rule
out the possibility that these residues directly interact
with the receptors. However, given that activity differ-
ences are observed over multiple receptors, it is more
likely that potency differences are a result of inherent
ligand differences (e.g., differences in ligand flexibility/
conformation). Furthermore, introducing the GDF11-
specific residues in the pre-helix loop (F49Y/V50M/
L52M), a region known to be important for receptor
specificity ([54]; reviewed in [38]), also results in in-
creased activity. Additionally, introduction of GDF11
fingertip residues, D89 and Q91, into GDF8 also signifi-
cantly increased ligand activity. However, our structural
data do not provide a molecular explanation for how
these variances confer differences in activity. Neverthe-
less, they do suggest that the potency differences
between GDF8 and GDF11 are a result of a combination
of the residue differences within and around the type I
binding interface.
Resolution of the apo-GDF8 and apo-GDF11 crystal
structures revealed that both ligands exhibit significant
conformational flexibility. Interestingly and despite the
high sequence identity, nearly identical crystallization
conditions resulted in two distinct conformations. Al-
though these conformations may be a result of the
crystallization process, it supports the idea that GDF8
and GDF11 are flexible enough to be trapped in alter-
nate states. However, an additional apo-GDF11 structure
revealed the ligand in the classic “open” conformation
and contained similar molecular contacts within the
wrist region that we observed in the FS288-bound state
[46]. Furthermore, under similar crystallization condi-
tions, additional TGFβ superfamily growth factors have
been solved in their apo states and adopt the classic
“open” conformation (reviewed in [38]). For example,
structures of several BMP ligands in the apo state all
exhibit the “open” configuration [77–81]. The extreme
“closed” conformation of GDF8 is not entirely unprece-
dented, as one structure of activin A in complex with
ActRIIB showed a similar “closed” configuration [62].
This was initially somewhat controversial; however, mul-
tiple activin A structures have since been determined
and support the notion that the activin A dimer is flex-
ible [82, 83]. It should be noted that this is not the first
example of GDF8 captured in an alternate conformation.
Recently, the co-crystal structure of GDF8 bound to a
neutralizing antibody was solved where the GDF8 lig-
and adopts an exaggerated “open” conformation [61],
resembling the apo-GDF11 structure presented here.
Furthermore, similar to activin A and GDF8, ligands of
the TGFβ subclass also exhibit significant flexibility
[60, 84–86]. In fact, the biological activity of different
TGFβ isoforms, which also share high overall sequence
identity, was shown to correlate with the rigidity of the
dimer, specifically the wrist helix [60]. However, we
cannot discount that the crystallization process has
trapped these ligands in alternate conformations. Add-
itional solution-based biochemical approaches are
needed to better understand ligand dynamics. Never-
theless, differences in the wrist region of GDF11 could
contribute to the increased ligand potency over GDF8
by either stabilizing the dimer interface or presentation
of the wrist/pre-helix loop to facilitate differential dir-
ect interaction with the type I receptors, or a combin-
ation thereof.
Our data strongly indicate that GDF11 is a more po-
tent signaling ligand compared to GDF8. While this ob-
servation has not been explicitly realized in the
literature, there is evidence suggesting that our results
are consistent in that GDF11 is a more potent ligand
than GDF8 [16, 44]. However, a recent study utilizing a
cell line with modified and potentially functionally inac-
tivated type II and type I receptors showed that GDF8
and GDF11 are nearly indistinguishable in terms of their
potential for type II and type I heterodimerization [87].
In this same study and using another assay, there was little
difference in the potentiation of downstream SMAD2/3
responsive elements between GDF8 and GDF11 [87].
Interestingly, we observed that differences in SMAD2/3
responsiveness between GDF8 and GDF11 were less pro-
nounced in the HepG2 cell line, the same cell line utilized
in [87]. We observed more robust differences between
GDF8 and GDF11 in other cell lines and in vivo. There-
fore, a potential explanation for these differences may be
due to the receptor profile of a particular cell type or
tissue in addition to other confounding factors such as co-
receptors. Given that GDF8 may not utilize the type I re-
ceptors as effectively as GDF11, it is tempting to speculate
that both potency and receptor utilization differentiate the
biological actions of GDF11 and GDF8.
Conclusions
In conclusion, we present evidence supporting the no-
tion that GDF8 and GDF11, despite their high sequence
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identity, are not functionally equivalent. Our data show
that GDF11 is a more potent activator of SMAD2/3 in
vitro and in vivo. GDF8 has been considered a somewhat
unique ligand of the TGFβ family due to dual utilization
of the type I receptors ALK4 and ALK5. Our data sug-
gest that GDF11 possesses these same attributes but,
due to differences in amino acid composition, utilizes
these receptors more effectively to initiate signal trans-
duction. Apart from additional regulatory alterations be-
tween GDF8 and GDF11, these ligands may have
evolved differences in relative potency through selective
pressure in order to provide an evolutionary advantage.
Methods
Purified proteins utilized in this study
Proteins used in this study were commercially purchased
or produced and purified as previously described with
minor alteration [47, 48, 50, 52–55, 88, 89]. Unless
otherwise noted, experiments were performed with pro-
teins produced and purified by the authors. Purchased
proteins were as follows: mature GDF8 (R&D Systems;
Cat. no. 788-G8-CF and PeproTech; Cat. no. 120-00),
mature GDF11 (R&D Systems; Cat. no. 1958-GD-010-
CF and PeproTech (Cat. no. 120-11); Fc-ALK5 (R&D
Systems; Cat. no. 3025-BR/CF), Fc-ActRIIB (R&D Sys-
tems; Cat. no. 339-RB/CF). Mature ligands purchased
from R&D Systems were reconstituted in 4 mM HCl,
0.01% bovine serum albumin (BSA). Mature ligands
purchased from PeproTech utilized in the in vitro stud-
ies were reconstituted in 4 mM HCl, 0.01% BSA. Pro-
duced and purified proteins are as follows: mature
GDF8 [6, 18, 47, 50, 54, 89], mature GDF11 [89], latent
GDF8/GDF11 chimeras (see below), mature activin A
[52, 55, 62], mature activin B (see below), mature
TGFβ3 [73], TβRII [73], FS288 [52, 54], FSTL3 [47, 55],
GASP1 and GASP2 [50, 90], ActRIIB-ECD [62], and
ALK5-ECD [73].
Activin B
Chinese hamster ovary (CHO)-DG44 cells were co-
transfected with linearized plasmids containing full-length
human activin B (pcDNA3) and dihydrofolate reductase
(pMT2). The transfected cells underwent multiple rounds
of clonal selection performed with increasing concentra-
tions of up to 1.24 μM methotrexate (MTX) to generate a
stable cell line expressing activin B. High expressing
clones were isolated and adapted to suspension culture in
SFM4CHO-Utility (HyClone). Activin B was produced by
adjusting the cells at 1 × 106 cells/mL to 5 mM sodium
butyrate and culturing for 8 days, after which the condi-
tioned medium was concentrated and purified as previ-
ously described [91].
GDF8/GDF11 chimeras
GDF11-like changes were introduced into a pRK5 plas-
mid containing wild-type full-length human GDF8
using site-directed mutagenesis. GDF8/GDF11 chimeric
protein was transiently produced using HEK293T co-
transfected with human furin in pcDNA4 using poly-
ethylenimine MAX (Polysciences, Inc.). Transfection
proceeded for 4 h in culture medium followed by ex-
change into serum-free media. Conditioned media were
collected 72–96 h later and concentrated 10 times. The
concentrated media were applied to a Superdex S200 col-
umn (Amersham Biosciences). Fractions containing the
latent complex were pooled and concentrated. Initial pro-
tein concentration and subsequent normalization were
done by quantification (ImageJ) of SDS-PAGE colloidal
Coomassie-stained gels.
GDF11:FS288 complex crystal structure determination
Purified GDF11 (Acceleron Pharma) was mixed with
FS288 at a 1:2.5 molar ratio and purified over a Super-
dex 200 column (Amersham Biosciences) similar to pre-
vious purification of the GDF8:FS288 complex [54]. The
protein was then concentrated to 6.6 mg/mL and mixed
1:1 in a hanging drop experiment with a solution con-
taining 125 mM phosphate citrate pH 4.2, 18% (w/v)
EtOH, and 1% (w/v) PEG 1000. Diffraction experiments
were performed at the Argonne National Laboratory
Advanced Photon Source 23ID beamline and processed
as previously described [54]. Phasing was performed by
molecular replacement using Phaser and the CCP4 suite
using one dimer of GDF8 and one monomer of FS288 as
the search model (PDB ID: 3HH2; [54]). Refinement was
carried out with Refmac and Phenix. Coordinates have
been deposited in the PDB (PDB ID: 5JHW).
apo-GDF8 crystal structure determination
Crystals of apo-GDF8 were obtained while attempting to
generate crystals of the GDF8:GASP1 complex. Purified
mature GDF8 [50, 54] was mixed at a 1:1.5 molar ratio
with purified GASP1 [50, 90], and the complex was puri-
fied as previously described [50]. The complex was con-
centrated to 10 mg/mL and mixed 1:1 in a hanging drop
experiment with a well solution containing 100 mM
MES pH 6.0 and 40% (w/v) 2-methyl-2,4-pentanediol
(MPD). Crystals were readily obtained in the presence of
noticeable protein precipitant. The resultant crystals
contained only GDF8. Diffraction experiments were per-
formed at the Argonne National Laboratory Advanced
Photon Source 21ID beamline. Phasing was performed
by molecular replacement using MolRep and the CCP4
suite using one monomer of GDF8 as the search model
(PDB ID: 3HH2; [54]). Refinement was carried out with
Refmac and Phenix. Coordinates have been deposited in
the PDB (PDB ID: 5JI1).
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apo-GDF11 crystal structure determination
Crystals of apo-GDF11 were obtained while attempting
to generate crystals of the GDF11:ActRIIB complex.
Purified mature GDF11, provided by Acceleron Pharma,
was mixed at a 1:2.1 ratio with purified ActRIIB-ECD,
and the complex was sized using a Superdex S75 column
(Amersham Biosciences). The complex was concentrated
to 7.5 mg/mL and mixed 1:1 in a hanging drop experi-
ment with a well solution containing 5 mM CaCl2,
0.1 M sodium acetate pH 3.75, and 33% MPD. Similar to
apo-GDF8, crystals were readily obtained in the presence
of noticeable precipitant. The resultant crystals con-
tained only GDF11. Diffraction experiments were per-
formed at the Argonne National Laboratory Advanced
Light Source 23-ID-D beamline. Phasing was performed
by molecular replacement using Phaser and the CCP4
suite using one monomer of GDF11 as the search model
(PDB ID: 5E4G). Refinement was carried out with
Refmac and Phenix. Coordinates have been deposited in
the PDB (PDB ID: 5UHM).
Luciferase reporter assays
HEK293 activity/potency and inhibition assays
The assays using the HEK293-(CAGA)12 luciferase re-
porter cells (initially derived from RRID: CVCL_0045)
were performed as previously described [47–50]. Cells
were seeded in a 96-well plate and grown for 24 h. For
the activity comparison assays, the growth medium was
then removed and replaced with serum-free medium +
0.1% BSA containing a twofold serial dilution series of
mature GDF8 or GDF11 for 18 h. Inhibition assays were
performed in a similar fashion, except that the ligand
was held at a final concentration of 0.62 nM and then
mixed with twofold serial dilutions of antagonist (FS288,
FSTL3, GASP1, GASP2, ActRIIB-ECD, Fc-ActRIIB; R&D
Systems). The cells were lysed and luminescence was re-
corded immediately using a Synergy H1 Hybrid plate
reader (BioTek). The activity data were imported into
GraphPad Prism and fit using a non-linear regression
with a variable slope to calculate the EC50 or IC50.
HEK293-GDF8/GDF11 chimeras
For these transfection assays, the HEK293-(CAGA)12 lu-
ciferase reporter cells were plated in a 96-well plate at
~2 × 104 cells/well, grown for 24 h, and transiently co-
transfected with plasmids containing GDF8/GDF11
chimeric constructs (25–100 ng; pRK5), human TLL2
(50 ng; pcDNA3), and human furin (50 ng; pcDNA4)
using Mirus LT-1 transfection reagent. Empty pRK5 vec-
tor was added for a total of 200 ng DNA transfected/
well. Transfection proceeded overnight followed by re-
moval of growth medium in exchange for serum-free
medium. Cells were cultured for an additional 24 h and
assessed for luciferase activity as described above. The
cells were plated and cultured similarly for the experi-
ments where exogenous complexes were added to the
cells. Following acid activation with 1 M HCl, the com-
plexes were neutralized with 1 M NaOH and diluted in
serum-free medium + 0.1% BSA. The culture medium
was removed and the media containing the complexes
was added to the cells. After 18–24 h, the cells were
lysed and assessed for luciferase activity. For the TLL2
activation experiments, the cells were transfected with
50 ng TLL2 24 h prior to treatment with complexes di-
luted in serum-free media + 0.01% BSA. Cells were lysed
18–24 h later and assessed for luciferase activity.
HepG2 and LβT2 activity assays
The luciferase and hormone assays in HepG2 (ATCC; Cat.
no. HB-8065; RRID: CVCL_0027) and LβT2 (kindly pro-
vided by Dr. Pamela Mellon, UCSD; RRID: CVCL_0398)
cells were performed as previously described [51, 92].
Ligands were purchased from commercial sources for
these experiments.
RIB L17 receptor utilization assays
The assays using RIB L17 (kindly provided by Dr. Joan
Massagué; RRID: CVCL_0596) cells were performed as
previously described with some minor alterations [54].
To increase the experiment scale, the assay was per-
formed in a 96-well plate. The cells were plated at ~2 ×
104 cells/well and grown for 24 h. The cells were then
co-transfected with a total of 100 ng DNA containing
the (CAGA)12 luciferase reporter construct (gift from
Dr. Anita Roberts [93]) and receptor containing plas-
mids (pRK5 rat ALK4, pRK5 rat ALK5, pcDNA3 human
ALK7) alone or in combination using Mirus LT-1 trans-
fection reagent. The ALK7 S270T variant was produced
via mutagenesis with the following primer set: forward,
GACTCAACTTTGGCTGGTAACTGAATATCATGAA-
CAGGG; reverse, CCCTGTTCATGATATTCAGTTAC-
CAGCCAAAGTTGAGTC. Empty pRK5 vector was
added to normalize the total DNA concentration. Trans-
fection proceeded overnight in culture medium followed
by media exchange to serum-free media + 0.1% BSA con-
taining 0.62 nM mature activin A, activin B, GDF8,
GDF11, or TGFβ3. After 8 h, the cells were lysed and
assessed for activity.
Surface plasmon resonance (SPR) studies
SPR analysis was performed similarly to previous stud-
ies [47, 50]. Briefly, experiments and protein dilutions
were carried out in HBS-EP+ buffer (10 mM HEPES,
pH 7.4, 500 mM NaCl, 3.4 mM EDTA, 0.05% P-20 sur-
factant, 0.5 mg/mL BSA) at 37 °C on a Biacore T200
optical biosensor system. All experiments were per-
formed using a CM5 biosensor chip. Proteins were
either immobilized by standard amine chemistry
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according to the manufacturer’s protocol or captured
by using immobilized Protein A. For the specific experi-
mental design, see the Results section. Data were ana-
lyzed using BIAevaluation software version 1.0.
Heparin affinity analysis
Determination of heparin affinity was performed as pre-
viously described [54]. Briefly, 100 μg of FS288 alone or
in complex with GDF8 or GDF11 was applied to a 1 mL
HiTrap column (Amersham Biosciences) and eluted with
a linear 2 M NaCl gradient over 120 column volumes.
Primary skeletal myoblasts
Primary skeletal myoblasts were isolated from limb mus-
cles of mice aged 8–12 weeks. After dissection, limb
muscles were washed in ice-cold phosphate-buffered sa-
line (PBS). Next, tissues were removed from PBS,
minced with surgical scissors, and placed in digestion
media (0.2% collagenase type II, 0.05% dispase in
DMEM) for 15 min while shaking at 37 °C. After diges-
tion, muscle slurries were triturated until smooth and
then digested for additional 8 min. 5 mL filtered donor
bovine serum was added to stop the enzymatic reaction
and the digestion, and the mixture was triturated again
until smooth followed by addition of PBS and centri-
fuged at 1600 rpm for 5 min. Pellets were resuspended
in PBS and filtered through a 70-μm cell strainer and
centrifuged at 1600 rpm for 5 min. Pellets were resus-
pended in growth media (20% horse serum, 1% Glutamax,
1% penicillin/streptomycin, 5 ng/mL bFGF (Sigma-
Aldrich) in F10 media) and added to coated culture
dishes (0.2% rat-tail collagen, 5 μg/mL natural mouse
laminin). Media were replaced after 48 h of culture.
Cells were grown for another 48 h before the culture
was enriched for myoblasts. Detached myoblasts were
collected and centrifuged at 1200 rpm for 5 min and
then re-plated on freshly coated culture dishes. Purity
of the myoblast culture was assessed microscopically,
and a second round of pre-plating was performed to
maximize the purity before treating primary myo-
blasts with commercially purchased GDF8 or GDF11
(PeproTech; Cat. no. 120-00 and Cat. no. 120-11,
respectively). Western analysis on cell lysates was
performed using phosphorylated SMAD2/3 (Cell sig-
naling; Cat. no. 8828S; Lot 6), total SMAD2/3 (Cell
signaling; Cat. no. 3102S; Lot 9), and GAPDH (Santa
Cruz; Cat. no. sc-25778; Lot I3015) primary anti-
bodies. Antibody detection was performed with
horseradish peroxidase-conjugated antibodies (Cell
signaling; Cat. no. 7074S; Lot 25) and enhanced
chemiluminescence (Amersham™ GE Healthcare; Cat.
no. 45-002-401).
In vivo injection of ligands into mice
All animal studies were performed as approved by the
Harvard Committee on Animals. Adult (1-year-old)
C57Bl/6 male mice were obtained from Charles River,
and intravenously injected (by tail vein injection) with
0.5 mg/kg GDF11 (PeproTech) or 0.5 mg/kg, 1 mg/kg,
2 mg/kg and 4 mg/kg GDF8 (R&D Systems) or saline as
control. Ligands were reconstituted in water at a con-
centration of 1 mg/mL and diluted in saline prior to
injection. Heart tissue was collected 1 h post injection.
Whole heart protein lysates were obtained by homogen-
izing the heart in RIPA buffer freshly supplemented with
1 mM PMSF and protein phosphatase inhibitor 2 and 3
(Sigma-Aldrich). 40 g total protein was loaded in
NuPAGE 4-12% Bis-Tris gels (LifeTechnologies). Follow-
ing transfer, membranes were blocked with non-fat dry
milk for 1 h at room temperature and successively incu-
bated with primary pSMAD2 antibody (Millipore, Cat.
no. AB3849; Lot 2649232) and total SMAD2/3 antibody
(Cell Signaling Technology, Cat. no. 8685P; Lot 4) over-
night at 4 °C. Proteins were detected with horseradish
peroxidase-conjugated antibodies (BioRad Laboratories;
Cat. no. 172-1019; Lot L006328 A) and enhanced
chemiluminescence (Amersham™ GE Healthcare, Cat.
no. RPN2236).
Additional files
Additional file 1: Table S1. Analysis of GDF8 and GDF11 activity in
HEK293, HepG2 and LβT2 cells [57, 94–96]. (DOC 30 kb)
Additional file 2: Figure S1. Potency of recombinant GDF8 and GDF11
from different sources. Luciferase reporter gene assay ((CAGA)12
promoter) following titration of GDF8 (blue) and GDF11 (orange) ligands
in HEK293 cells. Luciferase activity was assessed 18–24 h post ligand
treatment. The calculated EC50 value for each ligand source using non-
linear regression with variable slope is shown in the table below the
graph. Data information: Data are presented as percent GDF11 activation
after background subtraction (0 nM ligand concentration). Each point is
the mean ± SEM of three to four independent experiments. Ligand
sources are indicated in the graph. (TIF 750 kb)
Additional file 3: Figure S2. Pulse-chase treatment with GDF8 or
GDF11 reveals potency differences. A Short exposure to GDF11 results in
a significantly enhanced SMAD3-dependent response compared to GDF8.
The experimental design is such that the ligand was added to HEK293
cells stably transfected with the (CAGA)12 promoter driving the luciferase
gene for the indicated time followed by replacement of media without
ligand. Activity was measured 24 h after initial treatment. Cells were
treated with GDF8 or GDF11 at a ligand concentration of 620 pM. B
Time-dependent differences in the SMAD3 activation by GDF8 and
GDF11. Similar experimental design as in B, but instead cells were lysed
and assessed for luciferase activity at the indicated time of ligand treatment.
Cells were treated with GDF8 or GDF11 at a ligand concentration of 620
pM. Data information: Data are presented as fold activation above back-
ground (0 nM ligand concentration). Each point is the mean ± SEM of three
independent experiments. Curves were compared using two-way ANOVA
with Bonferroni correction (***P≤ 0.001). Ligand sources: GDF8 and GDF11
obtained from Acceleron Pharma. (TIF 256 kb)
Additional file 4: Figure S3. Sequence alignment of human BMP2,
GDF8, and GDF11. Gray bars above and below the sequence depict gross
topology of the ligands. Residues that interact with the type I receptor
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(blue) and type II receptor (yellow) are shown on BMP2 based on the
BMP2:ALK3:ActRIIA co-crystal structure (Protein Data Bank (PDB): 2GOO;
[97]). The non-identical residues between GDF8 and GDF11 are
highlighted in gray. (TIF 566 kb)
Additional file 5: Figure S4. Binding of GDF11 to the type I receptor
ALK5. A, B, C Steady state analysis for SPR traces shown in Fig. 7b and
calculated values. The maximum response at each concentration is
plotted to a steady state binding equation using Biacore T200 Evaluation
Software version 1.0 (Biacore). Sensorgrams were double referenced
using an average of two 0 nM ligand injections. Ligand sources: GDF8
and GDF11, gift from Acceleron Pharma; Activin A, Activin B, and TGFβ3,
produced and purified as described in “Methods.” D, E, F Ligand binding
to Fc-ActRIIB-ECD (A), Fc-ALK5-ECD (B), and ALK5-ECD (C) amine coupled
to a CM5 biosensor chip. Ligands were at 500 nM. TβRII, the type II receptor,
was required for TGFβ3 binding to Fc-ALK5-ECD and ALK5-ECD. The
receptor concentration was at 1 μM for this experiment. Experiments
were performed using 40 μL/min flow rate at 37 °C. (TIF 1166 kb)
Additional file 6: Figure S5. Purification and quantification of GDF8/
GDF11 chimeric ligands. A, B Representation of purified protein from
selected GDF8/GDF11 chimeras under non-reduced (A) and reduced (B)
conditions (4–15% gradient gel). Chimeras or empty vector control were
produced transiently using HEK293T cells and purified using size exclusion
chromatography. The resultant peak containing the prodomain:mature ligand
complex was pooled and concentrated. For empty vector control,
corresponding fractions from a similar retention volume were pooled.
The lane labeled “pro domain + mature” serves as a control for the
molecular weight of purified wt GDF8 prodomain and wt GDF8 mature
ligand. Note the expected changes in mass of the mature ligand (blue
arrows) under non-reducing (dimer) and reducing (monomer) conditions
while the prodomain mass is relatively unaffected (gray arrow). Protein is
visualized by colloidal Coomassie stain. To ensure that comparable amounts
of each GDF8/GDF11 chimeric protein were being administered in the
cell-based assays, we first normalized protein concentrations based on the
amount of dimer present in a non-reduced SDS-PAGE gel stained with
colloidal Coomassie. The samples were then normalized and reexamined by
SDS-PAGE gel under non-reducing and reducing gel. The subsequent bands
were quantified (bottom, below gel) under non-reduced (A) and reduced (B)
gels using ImageJ showing that the protein concentrations were indeed
normalized. 500 ng of recombinant GDF8 prodomain and purified GDF8
mature were loaded for reference. (TIF 3694 kb)
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